Related Experiment Video
Updated: Aug 7, 2026
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
[A nimodipine interventional study of patients with mild cognitive impairment]
Wei Wang1, Lu-ning Wang, Xiao-hong Zhang
1Department of Neurology, South Building, PLA General Hospital, Beijing 100853, China. wangwei301@hotmail.com
Objective:
To observe the effect of nimodipine on the cognition status and the changes of metabolites in brain tissue in the patients with mild cognitive impairment (MCI) in order to evaluate the significance of intervening MCI with medication.
Methods:
31 patients with MCI were selected 16 cases were in a treatment group taking nimodipine for 3 months besides taking basic internal medication and 15 cases in a control group taking only basic internal medication. Before and after treatment, multiple cognition tests were carried out in both groups and magnetic resonance spectroscopy (MRS) in Hippocampus region was carried out in 5 patients of the treatment group.
Results:
Verbal instant recall scores, symbol digit modalities test (SDMT) scores and mini-mental state examination (MMSE) total scores in the treatment group were improved significantly after treatment as compared with those in the control group (P < 0.05).
Conclusion:
Nimodipine can improve memory ability as well as attention ability of the patients with MCI to a certain extent and make the general cognition function improved.
Insights
Nimodipine treatment improved cognitive function in patients with mild cognitive impairment (MCI). Key measures of memory and attention showed significant enhancements, suggesting a therapeutic benefit for MCI.
Area of Science:
- Neurology
- Pharmacology
Background:
- Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia.
- Early intervention is crucial to potentially slow or reverse cognitive decline.
Purpose of the Study:
- To evaluate the efficacy of nimodipine in improving cognitive status in patients with MCI.
- To assess changes in brain metabolites associated with nimodipine treatment in MCI.
Main Methods:
- A randomized controlled trial involving 31 patients with MCI.
- Treatment group received nimodipine for 3 months; control group received standard care.
- Cognitive function assessed using verbal recall, SDMT, and MMSE; MRS performed on a subset.
Main Results:
- Significant improvements observed in verbal instant recall, SDMT, and MMSE scores in the nimodipine group compared to controls (P < 0.05).
- Nimodipine demonstrated a positive impact on memory and attention abilities.
Conclusions:
- Nimodipine shows potential as a therapeutic agent for improving cognitive function in individuals with MCI.
- The findings support the consideration of nimodipine for managing MCI symptoms.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:22Alzheimer's Disease: Treatment